the sensitivity of HRM discovery of mutations tried was higher or much like traditional sequencing. Multiple myeloma is a clonal condition of plasma cells which can be considered incurable with currently available solutions. Recently, advances in understanding that most of intracellular proteins contact us undergo degradation through the ubiquitin proteasome pathway which has a role in regulating cell proliferation, difference, survival and apoptosis have changed the treatment paradigm of myeloma. Asweall know, Bortezomib, the very first FDA approved proteasome chemical, has shown significant anti myeloma action and prolonged overall survival in MM patients. Nevertheless, you may still find some cases that not answer Bortezomib therapy initially or free awareness fundamentally. The identification of molec ular pathways and cellular mechanisms of drug sensitivity continue to be had a need to bypass them and allow this essential class of agent to remain vital in the management of MM. Arsenic trioxide and 2 methoxyestradiol show activity to induce apoptosis in myeloma Urogenital pelvic malignancy cells through multiple mechanisms, which made them potential remedies forMMand synergistic agent with other active anti myeloma drugs. Many clinical studies are currently wanting to examine their values in MM patients. To understand the elements in myeloma cells sensitivity to Bortezomib, associated molecular target ought to be examined. Catenin, the key protein of canonical Wnt signaling pathway,was around stated to advertise the proliferation and inhibit the apoptosis in myeloma cells by controlling its downstream gene expression. Besides, it has been reported that catenin accumulated in human epidermoid carcinoma cells after proteasome inhibitor lactacystin treatment, showing that catenin was changed via ubiquitin proteasome pathway. But little is known about whether Bortezomib treatment can up manage catenin in myeloma cells and whether up licensed catenin after Bortezomib treatment is active in the things of myeloma cells order Dasatinib sensitivity to Bortezomib. In this study, we asked: Whether there is any relationship between myeloma cells sensitivity to Bortezomib and their constitutive articles of catenin, How catenin changed after managing Bortezomib alone or combined with As2O3 and 2ME2 providers, and Whether the change of catenin is related to the sensitivity of myeloma cells to Bortezomib. Here we demonstrated that catenin protein was negatively from the sensitivity of myeloma cells to Bortezomib and As2O3/2ME2 could enhance the sensitivity of myeloma cells to Bortezomib and reduce the accumulation of catenin after inhibition. Myeloma mobile line CZ 1, which produces light chain protein, was recognized from the bone marrow of the patient with advanced level stage MM classified because the light chain enter our laboratory.